KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Notes Payables: 2011-2014

Historic Notes Payables for Travere Therapeutics (TVTX) over the last 2 years, with Dec 2014 value amounting to $40.5 million.

  • Travere Therapeutics' Notes Payables was N/A to $41.1 million in Q2 2015 from the same period last year, while for Jun 2015 it was $41.1 million, marking a year-over-year change of. This contributed to the annual value of $40.5 million for FY2014, which is N/A change from last year.
  • As of FY2014, Travere Therapeutics' Notes Payables stood at $40.5 million, which was up 61.94% from $25.0 million recorded in FY2011.
  • Over the past 5 years, Travere Therapeutics' Notes Payables peaked at $40.5 million during FY2014, and registered a low of $25.0 million during FY2011.
  • For the 1-year period, Travere Therapeutics' Notes Payables averaged around $40.5 million, with its median value being $40.5 million (2014).